View : 2 Download: 0

FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): Study protocol for randomized controlled trial

Title
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): Study protocol for randomized controlled trial
Authors
Kim J.-Y.Son J.-W.Park S.Yoo T.-H.Ryu D.-R.Chin H.J.Kim Y.-J.
Ewha Authors
류동열
SCOPUS Author ID
류동열scopus
Issue Date
2017
Journal Title
Trials
ISSN
1745-6215JCR Link
Citation
vol. 18, no. 1
Keywords
Chronic kidney diseaseDiabetes mellitusHypertensionProteinuria
Publisher
BioMed Central Ltd.
Indexed
SCIE; SCOPUS scopus
Abstract
Background: Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). Methods: This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP<140mmHg); fimasartan strict SBP control (SBP<130mmHg); losartan standard SBP control; and losartan strict SBP control. After 24weeks, all individuals are treated with fimasartan for an additional 120weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in proteinuria, which is assessed using the spot urine albumin-creatinine ratio at 24weeks. The secondary endpoints are the cardiovascular and renal outcomes at 144weeks compared between the strict SBP and standard SBP control groups. Discussion: The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria. Trial registration: Clinicaltrials.gov, NCT02620306. Registered on 1 December 2015. © 2017 The Author(s).
DOI
10.1186/s13063-017-2375-8
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE